The product of a single gene encoding proopiomelanocortin (POMC) is differentially processed to produce corticotropin and a-melanotropin in anterior and intermediate pituitary cells, respectively. Hormonal control of POMC gene transcription and of corticotropin or amelanotropin release is also tissue-specific; for example, glucocorticoids specifically inhibit anterior but not intermediate pituitary POMC transcription. Outside the pituitary gland, very low levels of POMC mRNAs are present in brain, testes, ovaries, and placenta. We have used transgenic mice to identify POMC 5' flanking sequences that are sufficient for tissuespecific expression and glucocorticoid regulation in anterior and intermediate pituitary cells. Three lines of transgenic mice were established, each carrying 50-75 copies (per cell) of a chimeric rPOMCneo gene constituted of rat POMC promoter sequences and of bacterial neomycin-resistance coding sequence. High levels of rPOMCneo transcripts were detected in pituitaries of mice from all three lineages. In situ hybridization revealed that the ratio of intermediate to anterior pituitary transcripts was similar for the transgene and endogenous POMC mRNA. rPOMCneo transcripts were not detected in any other tissue except at very low levels in the testes in two transgenic lines. Endogenous mouse POMC mRNA increased in response to depletion of plasma glucocorticoids (adrenalectomy) and decreased after glucocorticoid treatment; rPOMCneo transcripts were altered to the same extent by these treatments in all three lines. Intermediate pituitary and testicular rPOMCneo transgene expression was not altered by these treatments. Thus, no more than 769 base pairs of the rat POMC promoter are required for pituitary-specific expression and for specific glucocorticoid inhibition of the POMC gene in the anterior pituitary.
transcription is tissue-specific: POMC transcription is stimulated by corticotropin-releasing factor and inhibited by glucocorticoid hormones only in the anterior but not in the intermediate lobe of the pituitary (11) (12) (13) (14) . Thus, although POMC-expressing cells of the anterior and intermediate pituitary share a common embryological origin, they represent distinct cell types.
Previous work (15) defined rat POMC (rPOMC) promoter sequences required for expression in a POMC-expressing tumor cell line, ; POMC expression (regulation of transcription, processiig of precursor protein, and control of hormone release) is very similar in these cells and in anterior pituitary corticotrophs (1, 16) . These studies indicated that no more than 480 base pairs (bp) of 5' flanking POMC sequences were required for expression in AtT-20 cells. In addition, these promoter sequences were found to be inactive in other cell types. Transgenic mice offer the possibility to test directly the activity of POMC promoter sequences in every cell type in vivo, including all those expressing POMC (17) . We now report that a short POMC promoter fragment is entirely sufficient to confer tissue-specific expression and appropriate regulation by glucocorticoid hormones in the anterior and intermediate lobes of the pituitary.
MATERIALS AND METHODS
Transgenic Mice. The microinjected rPOMCneo DNA fragment was isolated from plasmid pPOMC706neo (15) by digestion with restriction enzymes Sal I and EcoRI and was purified as described (18, 19) . Fertilized ova were obtained from B6D2F1 females mated to B6C3F1 males and were microinjected and reimplanted as described (18, 19) . Genomic DNA, isolated from tail segments of the offspring (19) , was used to identify transgenic mice by Southern blot analysis (20) . Transgene sequences were revealed by hybridization with a randomly primed probe (21) RNA Analyses. Total RNA, isolated from various tissues by the guanidinium thiocyanate procedure (23), was usually quantitated by spectrophotometry at 260 nm except for the RNA samples prepared from dissected anterior and neurointermediate pituitaries. Since the amount of RNA extracted from four or five neurointermediate pituitaries is too low for spectrophotometry, we determined the RNA concentration in these samples by hybridization on dot blots with 32P-labeled (dT)12_18. For all RNA samples analyzed by both techniques, quantitation of poly(A)+ sequences by hybridization correlated very well with spectrophotometric quantitation (data not shown). Northern blots were prepared as Abbreviations: POMC, proopiomelanocortin; rPOMC, rat POMC; mPOMC, mouse POMC; nt, nucleotide(s).
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described (24) ; they were usually hybridized in sequence with (i) the same neo probe as above to reveal rPOMCneo transcripts, (ii) a 923-bp mouse POMC (mPOMC) cDNA fragment (25) to reveal endogenous mPOMC mRNA, and (iii) a 1500-bp rat brain ,8-actin cDNA probe (26) to reveal cellular f3/y-actin mRNA as internal control. The 5' ends of rPOMCneo and endogenous mPOMC transcripts were characterized by RNase mapping (27) using a rPOMC RNA probe (15, 28) that is perfectly homologous to the first 87 nucleotides (nt) of rPOMCneo transcripts but imperfectly matched to the first 63 nt of endogenous mPOMC mRNA (two mismatches and one nucleotide looping out). These mismatches decrease the stability of the hybrid between the probe and mPOMC mRNA, rendering it relatively sensitive to RNase. After hybridization of cellular RNA with the 32P-labeled probe, RNase digestion was for 1 hr in 300 ,ul at 370C with 12 jig of RNase A and 1000 units of RNase T1 (Fig. 3 ) or at 30°C with 4 ,ug of RNase A and 2000 units of RNase T1 (Fig. 4) .
In Situ Hybridization. The dissected pituitaries were immediately frozen on cryostat tissue holders and sectioned at -25°C at a thickness of 10 ,um. Sections were then mounted on gelatin-coated glass slides and air-dried for 10 min before fixation in 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Prehybridization and hybridization were performed as described (29) with the 32P-labeled mPOMC and neo probes described above. An optimal probe concentration of 2.5 x 105 cpm per 100 ,ul was used for each slide. Control slides were prepared in which the sections were pretreated with RNase A at 10 ,ug/ml or were hybridized with a pBR322 probe.
In Vivo Treatments. Adult male CSlBL/6J or transgenic mice were adrenalectomized by the dorsal route and provided with 0.9% NaCl drinking solution ad libitum. Two days after adrenalectomy or sham operation, mice (four per group) were injected subcutaneously twice daily with 20 ,ug of dexamethasone or with vehicle (0.9%o NaCl/1% gelatin). After (Fig. 1B) indicated that founder mouse 6 contained two separate chromosomal insertions (labeled 6A and 6B), which later segregated separately in a mendelian fashion. When genomic DNA isolated from mice of the three lineages was digested with the restriction enzyme BamHI, which cuts the injected DNA once, and hybridized with a neo probe, a predominant band of the same size as the microinjected rPOMCneo DNA fragment was detected, suggesting that multiple copies of the transgene were tandemly integrated in a head-to-tail array (17) . Comparison of this hybridization signal to known amounts of DNA indicated that mice of each line contain about 75 copies oftransgene per cell (Fig. 1B) . Thus, three different lines of transgenic mice (6A, 6B, and 36), each carrying about 75 copies of the rPOMCneo gene per cell, were established.
Tissue Distribution ofrPOMCneo Transgene Expression. To identify tissues expressing the rPOMCneo transgene, total RNA was isolated from various tissues of mice from the second generation of each transgenic line and analyzed by Northern blot hybridization. A specific neo probe revealed rPOMCneo transcripts in the pituitaries of both males and females of all three lineages ( Fig. 2 and data not shown). Testes of mice from lineages 6B and 36 were the only other tissues where rPOMCneo transcripts were detected. The following tissues were assayed for the presence of rPOMCneo transcripts: hypothalamus, brain, heart, kidneys, liver, lungs, seminal vesicles, epididymi, and ovaries (Fig. 2) . rPOMCneo transcripts of the expected size (-2600 nt) were observed in electroporated AtT-20 cells (Fig. 2 and ref. 15 ), in the pituitaries of all transgenic mice, and in the testes of lineage 36 mice. Testicular rPOMCneo transcripts were a few hundred nucleotides longer in mice of lineage 6B (Fig. 2) . Sequential rehybridization of the same blots with the mPOMC cDNA probe revealed high levels of POMC mRNA in the pituitary samples and much lower levels of the shorter POMC transcripts in the testes (Fig. 2) .
A more sensitive RNase mapping assay (15) was used to confirm and extend the results from Northern analysis. Even with this assay, no tissues other than those mentioned above were found to contain rPOMCneo transcripts (data not shown). As illustrated at the bottom of Fig. 3 (Fig. 3) . Thus, it appears that initiation ofrPOMCneo transcription occurred at the expected position within the POMC promoter and that similar levels of these transcripts are present in the pituitaries from the three lines of transgenic mice. A more quantitative analysis of mPOMC and rPOMCneo transcripts in isolated anterior and neurointermediate pituitaries revealed similar ratios of these transcripts in both tissues, suggesting that the transgene is expressed as efficiently in the two tissues of all three lines (Fig. 4 and data not shown) RNase mapping of testicular RNA from the three lines of transgenic mice revealed the expected 87-nt rPOMCneo protected fragment in mice of lineage 36 and 6B (Fig. 3) . Testicular RNA from mice of lineage 6B also produced many larger fragments. These results suggest that the larger testicular rPOMCneo transcripts detected by Northern blot analysis in mice of the 6B lineage (Fig. 2) may arise from heterogeneous initiation of transcription within the POMC promoter fragment at sites lying upstream of the site used in the pituitaries of the same mice. As observed for endogenous mPOMC mRNA, testicular rPOMCneo transcripts are at least 100 times less abundant than in pituitary. Thus, rPOMC promoter sequences present in the transgene are entirely 3 . RNase mapping analysis of the 5' ends of rPOMCneo transcripts present in the pituitary and testes of transgenic mice. As illustrated at the bottom of the figure, the RNA probe used in these experiments should protect a fragment of 63 nt by hybridization to authentic mPOMC mRNA present in pituitaries. In addition, the same probe should protect an 87-nt fragment by hybridization to rPOMCneo transcripts initiated at the expected site (15, 28) . By using this probe, rPOMCneo and mPOMC transcripts were analyzed in RNA samples from control C57BL/6J mice (lanes G) and from the three transgenic lines 6A, 6B, and 36. The amounts of total pituitary and testicular RNA used in the assay were 5 Total RNA was extracted from dissected anterior and neurointermediate pituitary tissues and assayed for rPOMCneo and mPOMC transcripts by using an RNA probe as described in Fig. 3 except that 1 and 0.1 Mug of total RNA were used for anterior and neurointermediate pituitary samples, respectively. The positions ofprotected fragments corresponding to endogenous mPOMC mRNA and rPOMCneo transcripts are shown by arrows. Lanes M, size markers. RNA from control AtT-20 cells provided mPOMC marker fragments. Negative controls contained no RNA or 5 Mg of liver RNA. A short exposure of the mPOMC fragment is shown at the bottom of A. sufficient for specific expression in both anterior and neurointermediate pituitary and may also contribute to appropriate extrapituitary POMC expression.
Glucocorticoid Regulation of Transgene. Glucocorticoid hormones inhibit anterior pituitary POMC transcription, whereas they do not affect POMC expression in the intermediate pituitary (11) and testes (31) . We have assessed glucocorticoid regulation of the rPOMCneo transgene by adrenalectomy, which reduces circulating glucocorticoid levels, and by administering the synthetic glucocorticoid dexamethasone. RNase mapping was used as above to quantitate rPOMCneo and mPOMC transcripts in anterior and neurointermediate pituitaries and in testes of sham-operated, adrenalectomized, and adrenalectomized, dexamethasone-treated transgenic and C57BL/6J mice.
As shown in Fig. 4A for mice of lineage 36, adrenalectomy increased anterior pituitary rPOMCneo and mPOMC transcripts by a factor of -2, and both transcripts were decreased by a factor of -4 after dexamethasone treatment of adrenalectomized mice. In contrast, no significant effect of either treatment was observed on neurointermediate rPOMCneo and mPOMC transcripts (Fig. 4B) (10) .
We have now shown in transgenic mice that a short promoter fragment of the rPOMC gene is entirely sufficient to confer tissue-specific pituitary expression and anterior pituitary-specific regulation by glucocorticoids. Transcript analyses (Fig. 4) and in situ hybridization (Fig. 5) The testis, which normally contains low levels of short POMC transcripts (4-6, 8, 9) , is the only extrapituitary tissue in which we detected rPOMCneo transcripts. Interestingly, rPOMCneo transcripts are detectable in the testes of only two lines of transgenic mice and at very different concentrations despite the fact that the pituitaries of the same animals expressed the transgene at similar levels (Fig. 3) . In addition, in line 6B the majority of testicular transcripts appear to have aberrant 5' ends. It is difficult to link this observation to the normal use of a different start site for testicular transcription of endogenous POMC transcription (8, 9) , but it does suggest that POMC promoter sequences present in the transgene may be involved in testicular expression of POMC. Failure to detect rPOMCneo transcripts in hypothalamus, ovaries, or brain, which express very low levels of endogenous POMC (2) , may indicate that the transgene is not expressed in these tissues. However, if rPOMCneo transcripts were present in these tissues at the same abundance relative to mPOMC mRNA as observed in the pituitary, they would be below the predicted detection limit of the RNase or Northern assays.
Further work will be needed to determine whether POMC sequences other than those present in this transgene are required for extrapituitary expression.
In conclusion, we have demonstrated that a 769-bp rat POMC promoter fragment directs expression in a highly specific manner to both the anterior and the intermediate pituitary gland of transgenic mice. In contrast to the apparently equivalent recognition of this promoter in the two pituitary tissues, glucocorticoids inhibit only anterior pituitary transcription. The POMC promoter may thus be useful for ectopic expression of gene products in transgenic mice where, in particular, the ability of corticotrophs and melanotrophs to efficiently process and secrete products may be of advantage.
